Trial Profile
Metabolic effects of ARA 290 in patients with type 2 diabetes mellitus and moderate kidney damage
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 05 Jan 2015
Price :
$35
*
At a glance
- Drugs Cibinetide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Proof of concept; Therapeutic Use
- Sponsors Araim Pharmaceuticals
- 05 Jan 2015 New trial record
- 15 Dec 2014 This proof-of-concept study will be initiated in 2015, according to a North Shore-Long Island Jewish Health System media release.